Related Experiment Videos
Effect of mepindolol on serum lipids
International Journal of Clinical Pharmacology, Therapy, and Toxicology
|November 1, 1982
Summary
Mepindolol, a beta blocker, significantly increased serum triglycerides in healthy subjects. However, it did not alter total cholesterol, HDL cholesterol, or LDL cholesterol levels, suggesting a neutral effect on cholesterol metabolism.
Area of Science:
- Cardiology
- Pharmacology
- Biochemistry
Background:
- Atherosclerosis is linked to plasma lipid levels.
- Beta blockers are commonly used for cardiovascular conditions.
- Understanding beta blockers' effects on lipids is crucial for patient management.
Purpose of the Study:
- To investigate the impact of mepindolol, a nonselective beta blocker with intrinsic sympathomimetic activity, on serum lipid profiles.
- To determine if mepindolol affects lipid distribution among lipoproteins, particularly HDL cholesterol.
Main Methods:
- Eighteen healthy subjects received daily oral doses of mepindolol (0.2 mg/kg).
- Fasting serum levels of total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides were measured before and after treatment.
- The LDL cholesterol/HDL cholesterol ratio was calculated.
Main Results:
- Mepindolol treatment resulted in a significant increase in serum triglycerides (+20.9%, p<0.01).
- No significant changes were observed in total cholesterol (-1.9%), LDL cholesterol (-6%), or HDL cholesterol (-0.%).
- The LDL cholesterol/HDL cholesterol ratio remained unchanged.
Conclusions:
- Mepindolol primarily increases serum triglyceride levels without affecting cholesterol concentrations or lipoprotein distribution.
- Unlike some other beta blockers, mepindolol does not appear to negatively impact HDL cholesterol levels.
- These findings suggest mepindolol may have a more favorable lipid profile compared to other beta-blocking agents regarding atherosclerosis risk.